DXP Enterprises, Inc. Announces Acquisition of Mequipco Ltd. DXP Enterprises, Inc. announced that it has completed the acquisition of Mequipco Ltd. Founded in 1974, Mequipco is headquartered in Calgary, Alberta Canada and operates out of three locations servicing Western Canada including…
Neo7Bioscience & McCullough Foundation Expose 3.5-Year Spike Persistence, Cancer Genomic Integration & mRNA Gene Chaos — Personalized Precision Peptides Restore Critically Injured Patients Neo7Bioscience, a leader in aHI-driven personalized molecular solutions, announced compelling evidence of prolonged SARS-CoV-2 Spike protein persistence…
Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma Estrella Immunopharma, Inc. a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases,…
Fresenius Announces FDA and EMA Acceptance for Review of Vedolizumab Biosimilar Candidate Fresenius Kabi, an operating company of Fresenius, announced that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics…
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate Polpharma Biologics International AG announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License…
Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones Contineum Therapeutics, Inc. a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today reported its second-quarter 2026 financial results…
Enhertu® Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer Enhertu® (trastuzumab deruxtecan) in combination with pertuzumab has been recommended for approval in the European Union (EU) for the first-line…
MindWalk Showcases ReefIQ™ for AI Drug Discovery at AMD Advancing AI MindWalk Holdings Corp. a Bio-Native AI company, today unveiled the first public demonstration of ReefIQ™, its biological context layer for AI drug discovery, running on AMD Instinct™ at AMD’s…
Vultr and AMD Support the University of Cambridge’s TESSERA AI Project to Accelerate Global Environmental Monitoring Vultr, the world’s largest privately-held cloud infrastructure company, and AMD, a leader in high-performance and AI computing, have announced their support for the University of…
N-Zyme Biomedical Closes US$4.6 Million Series A Financing to Advance Clinical Development N-Zyme Biomedical announced the successful closing of its Series A financing, raising approximately US$4.6 million to accelerate the advancement of its Phase 2 clinical programs and further the development of…
bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD bioAffinity Technologies, Inc. a biotechnology company advancing early-stage cancer diagnostics and targeted therapeutics, today announced a collaboration with Pictor®, Inc., a targeted proteomic platform company, to…
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 2026 Meiji Seika Pharma Co., Ltd. announced that results from the global Phase III…